Aquestive Therapeutics, Inc. AQST Change in Deferred Revenue
Change in Deferred Revenue at other companies
Other financials
Where this comes from
Reported directly by Aquestive Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInDeferredRevenue.
The official record: Aquestive Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aquestive Therapeutics, Inc.'s change in deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aquestive Therapeutics, Inc.'s change in deferred revenue?
- Aquestive Therapeutics, Inc. (AQST) reported change in deferred revenue of -$272K in Q1 2026.
- How has Aquestive Therapeutics, Inc.'s change in deferred revenue changed year-over-year?
- Aquestive Therapeutics, Inc.'s change in deferred revenue decreased by 4.2% year-over-year, from -$261K to -$272K.
- What is the long-term trend for Aquestive Therapeutics, Inc.'s change in deferred revenue?
- Over 2 years (2021 to 2024), Aquestive Therapeutics, Inc.'s change in deferred revenue has grown at a 84.9% compound annual growth rate (CAGR), from $3.76M to -$12.84M.
- What does change in deferred revenue mean?
- Change in payments received from customers for goods/services not yet delivered — a key SaaS and subscription metric.